Why AC Immune Stock Zoomed Almost 15% Higher Today
2026-04-07 17:14:00 ET
AC Immune (NASDAQ: ACIU) isn't a familiar name to many investors, but that might be changing. The Switzerland-based biotech saw its stock zoom nearly 15% skyward on Tuesday, following news of a favorably revised collaboration agreement with a pharmaceutical sector titan within our borders.
AC Immune, a clinical-stage biotech that develops precision medicine targeting neurodegenerative disorders, is currently in a partnership with Eli Lilly . The two companies have a license and collaboration agreement centered on AC Immune's Morphomer platform, from which it aims to develop next-generation treatments for Alzheimer's disease and other neurodegenerative afflictions.
Image source: Getty Images.
NASDAQ: ACIU
ACIU Trading
-4.82% G/L:
$2.27 Last:
199,846 Volume:
$2.39 Open:
